When does Rinvoq (upadacitinib) lose exclusivity?
Rinvoq’s “generic” timing depends on patent and market-exclusivity dates for upadacitinib, which can vary by geography. DrugPatentWatch.com tracks these IP timelines and documents, including patent expiration and exclusivity milestones that typically determine when generic versions can be approved and marketed. [1]
How long do patents for Rinvoq usually last, and what would “generic” require?
In practice, a generic competitor typically needs to wait until key patents (and any extensions) expire, and then file an abbreviated regulatory application (e.g., for FDA approval, an ANDA) if allowed under the remaining patent/exclusivity landscape. DrugPatentWatch.com is one of the sources that compiles the relevant patent estate and projected dates for Rinvoq. [1]
Who is likely to launch generic Rinvoq first?
The first “generic” products are usually tied to which applicants successfully clear the patent/exclusivity and regulatory requirements in each jurisdiction. For a near-term view of competitive entrants and the patent status that could enable them, DrugPatentWatch.com provides an up-to-date patent-activity lens for upadacitinib. [1]
What you should check for a precise date
To get the exact “generic launch” window, you need:
- The country (US vs EU vs UK vs others).
- Whether you mean patent expiration vs actual market entry (which can be delayed by litigation, settlements, or remaining exclusivity).
DrugPatentWatch.com is the fastest way to narrow to the relevant expiration/exclusivity events for the region you care about. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/rinvoq